Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease
Introduction
Various conditions, including mitochondrial defects, oxidative stress, and aberrant protein aggregation, may contribute to disrupt the physiological dynamics of apoptosis within the substantia nigra pars compacta (SNc), thus triggering the degenerative process underlying Parkinson's disease (PD) (Sherer et al., 2001). Monoamine oxidase type B (MAO-B) inhibitors of the propargylamine family have been extensively investigated for their potential neuroprotective properties (Tatton et al., 2003). The prototype of this class of compounds, selegiline, has shown antioxidant and neuroprotective effects in experimental studies, although the neuroprotective activity in PD patients has remained controversial (Tatton et al., 2003). Considerable attention has been recently attracted by rasagiline [R(+)-N-propargyl-1-aminoindane], the most potent propargylamine, which, although structurally related to selegiline, is different in that it is not metabolized to amphetamine and/or metamphetamine Finberg et al., 1999, Youdim et al., 2001a. Phase III clinical studies have already reported significant efficacy of rasagiline for PD treatment, either as adjunct therapy to l-Dopa (Rabey et al., 2000) or as monotherapy in early PD (Parkinson Study Group, 2002).
Numerous studies have reported that rasagiline can prevent cell death induced by various stimuli. In vitro, the drug has shown anti-apoptotic activity in partially–neuronally differentiated rat PC-12 cells treated with pro-apoptotic agents (Maruyama et al., 2001); rasagiline also increases the expression of anti-apoptotic and prosurvival proteins Akao et al., 2002b, Youdim et al., 2003, and reduces markers of altered mitochondrial activity Akao et al., 2002b, Naoi et al., 2002). Recent studies have shown that treatment with rasagiline protects against serum, and nerve growth factor withdrawal induced death in PC-12 cells (Am et al., 2004), and increases the expression of glial cell line-derived neurotrophic factor in human dopamine-derived neuroblastoma cells (SH-SY5Y) through the activation of the nuclear transcription factor NF-κB (Maruyama et al., 2004). Rasagiline has also shown potent activity against 6-hydroxydopamine (6-OHDA) toxicity, both in PC-12 and SH-SY5Y cells (Maruyama et al., 2000). Similar effects have been observed for the S-isomer of rasagiline, which is 1000 times less active on MAO (Youdim et al., 2001a), thus suggesting that MAO-B inhibition may not be central in the protective activity of the drug, which is likely related to intrinsic anti-apoptotic properties Abu-Raya et al., 2002, Akao et al., 2002b, Youdim et al., 2001b, Youdim et al., 2003. Neuroprotection by rasagiline has been substantially confirmed in vivo with several animal models Huang et al., 1999, Speiser et al., 1999; however, relatively few data are available on the ability of rasagiline to block SNc degeneration in animal models of PD, particularly after chronic administration. In fact, rasagiline and—previously—its racemate, AGN 1135, have proven able to prevent the nigrostriatal damage induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), in monkeys, when given before the toxin Heikkila et al., 1985, Kupsch et al., 2001. In this study, we explored the neuroprotective potential of chronic rasagiline administration in a rodent model of PD based on the intrastriatal injection of 6-OHDA, a procedure that causes a slowly evolving lesion of dopaminergic cell bodies in the SNc and is therefore recommended for neuroprotection studies (Deumens et al., 2002).
Section snippets
Animals
All animal care and use were in accordance with the European Convention for animal Care and Use of Laboratory Animals and were approved by the local Animal Care Committee. Male Sprague–Dawley rats (Charles River, Calco, LC, Italy), weighing 250–280 g at the beginning of the experiment, were housed two per cages at 20–22°C on a 12-h light–dark cycle with food and water ad libitum.
Surgery and treatment
Animals were anesthetized with 50 mg/kg of sodium-thiopental and placed in a stereotaxic frame (Stoelting, Wood Dale,
Results
Lesioned control animals showed consistent reduction of TH-positive cells in the right SNc, compared to the intact side, with a neuronal loss of 68.6% (Figs. 1A, B). Cell loss in the SNc was also confirmed by the evaluation of Nissl-stained sections (data not shown). Rasagiline treatment induced a considerable decrease of dopaminergic cell loss in the SNc with both doses displaying similar efficacy (0.8 mg/kg: 39.2% cell loss; 2.5 mg/kg: 32.5% cell loss; Fig 1B).
In control animals, 6-OHDA
Discussion
The results of our study show that rasagiline significantly counteracts the SNc cell loss following striatal injection of 6-OHDA in rats. Indeed, daily treatment with rasagiline doubled the percentage of cell survival in the lesioned SNc, with respect to control animals. The mechanisms underlying 6-OHDA neurotoxicity are incompletely understood, a major role being played by the pro-oxidant activity of the toxin, which easily autooxidizes. The toxin can also inhibit activity of the mitochondrial
Acknowledgements
The authors thank Dr. Alberta Samuele for her technical support. This work has been supported by Teva Pharmaceutical Industries Ltd. (Netanya, Israel).
References (26)
- et al.
Neuroprotective and neurotoxic effects of monoamine oxidase-B inhibitors and derived metabolites under ischemia in PC12 cells
Eur. J. Pharmacol
(2002) - et al.
An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cells
Neurosci. Lett
(2002) - et al.
Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-parkinson drugs rasagiline and selegiline
Neurosci. Lett
(2004) - et al.
Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease
Prog. Neurobiol
(2001) - et al.
Chronic clorgyline and pargyline increase apomorphine-induced stereotypy in the rat
Pharmacol. Biochem. Behav
(1985) - et al.
Enhancing effect of rasagiline on superoxide dismutase and catalase activities in the dopaminergic system in the rat
Life Sci
(2000) - et al.
Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway
Exp. Neurol
(2002) - et al.
Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse
Eur. J. Pharmacol
(1999) - et al.
N-propargyl-1(R)-aminoindan, rasagiline, increases glial cell line-derived neurotrophic factor (GDNF) in neuroblastoma SH-SY5Y cells trough activation of NF-κB transcription factor
Neurochem. Int
(2004) - et al.
The essentiality of Bcl-2, PKC and proteasome–ubiquitin complex activations in the neuroprotective-antiapoptotic action of the anti-Parkinson drug, rasagiline
Biochem. Pharmacol
(2003)
Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan
J. Neurochem
Pharmacological properties of the anti-Parkinson drug rasagiline: modification of endogeneous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours
Neuropharmacology
Pharmacology of rasagiline (N-propargyl-1R-aminoindan)
Adv. Neurol
Cited by (114)
Pathological remodelling of colonic wall following dopaminergic nigrostriatal neurodegeneration
2020, Neurobiology of DiseaseIdentification of antiparkinsonian drugs in the 6-hydroxydopamine zebrafish model
2020, Pharmacology Biochemistry and BehaviorSimultaneous bioanalysis of rasagiline and its major metabolites in human plasma by LC-MS/MS: Application to a clinical pharmacokinetic study
2016, Journal of Pharmaceutical and Biomedical AnalysisCitation Excerpt :Rasagiline (N-propargyl-1(R)-aminoindan) is a monoamine oxidase type-B (MAO-B) inhibitor that is usually used as a monotherapy in early Parkinson’s disease (PD) and as an adjunct medication in advanced PD to decrease off-time and improve the symptoms of PD in levodopa-treated patients with motor fluctuations [1–4]. Rasagiline also provides neuroprotective effects in laboratory models of neurodegeneration [5–8]. Rasagiline undergoes almost complete biotransformation in the liver, and two main pathways are involved in the metabolism of rasagiline, which include N-dealkylation and/or hydroxylation to yield 1-aminoindan (AI), 3-hydroxy-N-propargyl-1-aminoindan (3-OH-PAI) and 3-hydroxy-1-aminoindan (3-OH-AI) [9–11].